Literature DB >> 21102251

Mammalian target of rapamycin, Akt, and phosphatidylinositol 3-kinase signaling.

Sumanta K Pal1, Karen L Reckamp.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21102251      PMCID： PMC3192015          DOI： 10.1097/01.JTO.0000391378.17179.8f

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  9 in total

1.  Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis.

Authors:  Jian-Min Tang; Quan-Ying He; Rui-Xia Guo; Xiu-Jun Chang
Journal:  Lung Cancer       Date:  2006-02       Impact factor: 5.705

2.  Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors.

Authors:  Junji Tsurutani; Junya Fukuoka; Hiroko Tsurutani; Joanna H Shih; Stephen M Hewitt; William D Travis; Jin Jen; Phillip A Dennis
Journal:  J Clin Oncol       Date:  2005-12-05       Impact factor: 44.544

3.  BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines.

Authors:  A K Wong; F Shanahan; Y Chen; L Lian; P Ha; K Hendricks; S Ghaffari; D Iliev; B Penn; A M Woodland; R Smith; G Salada; A Carillo; K Laity; J Gupte; B Swedlund; S V Tavtigian; D H Teng; E Lees
Journal:  Cancer Res       Date:  2000-11-01       Impact factor: 12.701

4.  Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer.

Authors:  Daniel T Milton; Gregory J Riely; Christopher G Azzoli; Jorge E Gomez; Robert T Heelan; Mark G Kris; Lee M Krug; William Pao; Barbara Pizzo; Naiyer A Rizvi; Vincent A Miller
Journal:  Cancer       Date:  2007-08-01       Impact factor: 6.860

5.  Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.

Authors:  Shi-Yong Sun; Laura M Rosenberg; Xuerong Wang; Zhongmei Zhou; Ping Yue; Haian Fu; Fadlo R Khuri
Journal:  Cancer Res       Date:  2005-08-15       Impact factor: 12.701

6.  Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions.

Authors:  Binaifer R Balsara; Jianming Pei; Yasuhiro Mitsuuchi; Robert Page; Andres Klein-Szanto; Hao Wang; Michael Unger; Joseph R Testa
Journal:  Carcinogenesis       Date:  2004-07-07       Impact factor: 4.944

7.  Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung.

Authors:  Montserrat Sanchez-Cespedes; Paola Parrella; Manel Esteller; Shuji Nomoto; Barry Trink; James M Engles; William H Westra; James G Herman; David Sidransky
Journal:  Cancer Res       Date:  2002-07-01       Impact factor: 12.701

8.  Tobacco carcinogen-induced cellular transformation increases activation of the phosphatidylinositol 3'-kinase/Akt pathway in vitro and in vivo.

Authors:  Kip A West; Ilona R Linnoila; Steven A Belinsky; Curtis C Harris; Phillip A Dennis
Journal:  Cancer Res       Date:  2004-01-15       Impact factor: 12.701

9.  Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition.

Authors:  Alexandra C Racanelli; Scott B Rothbart; Cortney L Heyer; Richard G Moran
Journal:  Cancer Res       Date:  2009-06-23       Impact factor: 12.701
  9 in total
  1 in total

1.  Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours.

Authors:  S A Piha-Paul; P N Munster; A Hollebecque; G Argilés; O Dajani; J D Cheng; R Wang; A Swift; A Tosolini; S Gupta
Journal:  Eur J Cancer       Date:  2015-07-18       Impact factor: 9.162
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.